Neuroglial activation and neuroinflammation in the brain of patients with autism

Annals of Neurology

Volumn 57, Issue 1, 2005, Pages 67-81

  Vargas, Diana L ^a   Nascimbene, Caterina ^a,b   Krishnan, Chitra ^a   Zimmerman, Andrew W ^a,c   Pardo, Carlos A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUTISM; AUTOPSY; BRAIN TISSUE; CEREBELLUM; CEREBROSPINAL FLUID EXAMINATION; CHILD; CINGULATE GYRUS; CLINICAL ARTICLE; COMMUNICATION DISORDER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEVELOPMENTAL DISORDER; ENCEPHALITIS; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; FRONTAL LOBE; FROZEN SECTION; GLIA; HEREDITY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCYTOCHEMISTRY; INFLAMMATION; MACROGLIA; MALE; MENTAL DEFICIENCY; MICROGLIA; PATHOGENESIS; PRIORITY JOURNAL; SOCIAL INTERACTION; WHITE MATTER;

ADOLESCENT; ADULT; AUTISTIC DISORDER; BLOTTING, WESTERN; BRAIN DISEASES; CELL DIFFERENTIATION; CHEMOKINES; CHILD; CHILD, PRESCHOOL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MIDDLE AGED; NEUROGLIA; PROTEIN ARRAY ANALYSIS; STATISTICS, NONPARAMETRIC;

EID: 11144230769     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20315     Document Type: Article

References (64)

1. Rapin I. Autism. N Engl J Med 1997;337:97-104.
2. Lord C, Cook EH, Leventhal BL, et al. Autism spectrum disorders. Neuron 2000;28:355-363.
3. Rapin I, Katzman R. Neurobiology of autism. Ann Neurol 1998;43:7-14.
4. Newschaffer CJ, Fallin D, Lee NL. Heritable and nonheritable risk factors for autism spectrum disorders. Epidemiol Rev 2002;24:137-153.
5. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord 2003;33:365-382.
6. Bertrand J, Mars A, Boyle C, et al. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 2001;108:1155-1161.
7. Yeargin-Allsopp M, Rice C, Karapurkar T, et al. Prevalence of autism in a US metropolitan area. JAMA 2003;289:49-55.
8. Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001;2:943-955.
9. Korvatska E, Van de WJ, Anders TF, et al. Genetic and immunologic considerations in autism. Neurobiol Dis 2002;9:107-125.
10. Lipkin WI, Hornig M. Microbiology and immunology of autism spectrum disorders. Novartis Found Symp 2003;251:129-143.
11. Kemper TL, Bauman M. Neuropathology of infantile autism. J Neuropathol Exp Neurol 1998;57:645-652.
12. Bailey A, Luthert P, Dean A, et al. A clinicopathological study of autism. Brain 1998;121:889-905.
13. Bauman ML, Kemper TL. The neuropathology of the autism spectrum disorders: what have we learned? Novartis Found Symp 2003;251:112-122.
14. Licinio J, Alvarado I, Wong ML. Autoimmunity in autism. Mol Psychiatry 2002;7:329.
15. Gupta S, Aggarwal S, Rashanravan B, et al. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 1998;85:106-109.
16. Singh VK, Warren R, Averett R, et al. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol 1997;17:88-90.
17. Vojdani A, Campbell AW, Anyanwu E, et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 2002;129:168-177.
18. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001;120:170-179.
19. Dalton P, Deacon R, Blamire A, et al. Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol 2003;53:533-537.
20. Comi AM, Varsou A, Heyes MP, et al. Quinolinic acid and neopterin in children with autism: an analysis of cerebrospinal fluid. Ann Neurol 1999;46:528-529.
21. Zimmerman AW. Commentary: immunological treatments for autism: in search of reasons for promising approaches. J Autism Dev Disord 2000;30:481-484.
22. Guerin P, Lyon G, Barthelemy C, et al. Neuropathological study of a case of autistic syndrome with severe mental retardation. Dev Med Child Neurol 1996;38:203-211.
23. Lord C, Pickles A, McLennan J, et al. Diagnosing autism: analyses of data from the Autism Diagnostic Interview. J Autism Dev Disord 1997;27:501-517.
24. Scahill L, Lord C. Subject selection and characterization in clinical trials in children with autism. CNS Spectr 2004;9:22-32.
25. Gundersen HJ, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988;96:379-394.
26. Vehmas AK, Kawas CH, Stewart WF, et al. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 2003;24:321-331.
27. Huang RP. Cytokine protein arrays. Methods Mol Biol 2004;278:215-232.
28. Lin Y, Huang R, Chen LP, et al. Profiling of cytokine expression by biotin-labeled-based protein arrays. Proteomics 2003;3:1750-1757.
29. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998;43:465-471.
30. Aloisi F. Immune function of microglia. Glia 2001;36:165-179.
31. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
32. Bauer J, Rauschka H, Lassmann H. Inflammation in the nervous system: the human perspective. Glia 2001;36:235-243.
33. Medzhitov R, Janeway CA Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998;10:351-353.
34. Aloisi F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv Exp Med Biol 1999;468:123-133.
35. McGeer PL, Kawamata T, Walker DG, et al. Microglia in degenerative neurological disease. Glia 1993;7:84-92.
36. Teismann P, Tieu K, Cohen O, et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003;18:121-129.
37. Henkel JS, Engelhardt JI, Siklos L, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004;55:221-235.
38. Glass JD, Wesselingh SL. Microglia in HIV-associated neurological diseases. Microsc Res Tech 2001;54:95-105.
39. Gartner S. HIV infection and dementia. Science 2000;287:602-604.
40. Banati RB, Gehrmann J, Schubert P, et al. Cytotoxicity of microglia. Glia 1993;7:111-118.
41. Gebicke-Haerter PJ. Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 2001;54:47-58.
42. Auld DS, Robitaille R. Glial cells and neurotransmission: an inclusive view of synaptic function. Neuron 2003;40:389-400.
43. Fields RD, Stevens-Graham B. New insights into neuron-glia communication. Science 2002;298:556-562.
44. Nedergaard M, Ransom B, Goldman SA. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci 2003;26:523-530.
45. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001;2:734-744.
46. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002;3:216-227.
47. Rezaie P, Male D. Colonisation of the developing human brain and spinal cord by microglia: a review. Microsc Res Tech 1999;45:359-382.
48. Wierzba-Bobrowicz T, Kosno-Kruszewska E, Gwiazda E, et al. Major histocompatibility complex class II (MHC II) expression during the development of human fetal cerebral occipital lobe, cerebellum, and hematopoietic organs. Folia Neuropathol 2000;38:111-118.
49. McGeer PL, McGeer EG. Innate immunity, local inflammation, and degenerative disease. Sci Aging Knowledge Environ 2002;2002:re3.
50. Courchesne E, Yeung-Courchesne R, Press GA, et al. Hypoplasia of cerebellar vermal lobules VI and VII in autism. N Engl J Med 1988;318:1349-1354.
51. Courchesne E. Neuroanatomic imaging in autism. Pediatrics 1991;87:781-790.
52. Carper RA, Courchesne E. Inverse correlation between frontal lobe and cerebellum sizes in children with autism. Brain 2000;123:836-844.
53. Kinnear KJ. Purkinje cell vulnerability and autism: a possible etiological connection. Brain Dev 2003;25:377-382.
54. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990;11:97-101.
55. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003;15:23-32.
56. Kelder W, McArthur JC, Nance-Sproson T, et al. Betachemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 1998;44:831-835.
57. Losy J, Zaremba J. Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke 2001;32:2695-2696.
58. Eugenin EA, D'Aversa TG, Lopez L, et al. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem 2003;85:1299-1311.
59. Peterson KE, Errett JS, Wei T, et al. MCP-1 and CCR2 contribute to non-lymphocyte-mediated brain disease induced by Fr98 polytropic retrovirus infection in mice: role for astrocytes in retroviral neuropathogenesis. J Virol 2004;78:6449-6458.
60. Meng SZ, Oka A, Takashima S. Developmental expression of monocyte chemoattractant protein-1 in the human cerebellum and brainstem. Brain Dev 1999;21:30-35.
61. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-161.
62. Chen W, Frank ME, Jin W, et al. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001;14:715-725.
63. Mundy P. Annotation: the neural basis of social impairments in autism: the role of the dorsal medial-frontal cortex and anterior cingulate system. J Child Psychol Psychiatry 2003;44:793-809.
64. Franciotta D, Martino G, Zardini E, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001;115:192-198.